A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
NCT ID: NCT04596631
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
132 participants
INTERVENTIONAL
2020-11-02
2026-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Semaglutide - max. tolerated dose
Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
Oral semaglutide
Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
Placebo (semaglutide)
Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
Placebo (semaglutide)
Placebo treatment for 52 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral semaglutide
Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
Placebo (semaglutide)
Placebo treatment for 52 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, aged 10 to below 18 years at the day of randomisation
* HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)
* Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with:
* stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening) or
* stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin is defined as basal insulin treatment equal to or more than 30 days prior to screening, compared to the dose at screening, dose adjustments of ± 25% are allowed) or
* stable dose of basal insulin
Exclusion Criteria
* Maturity onset diabetes of the young (MODY)
* Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
10 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor and Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Ped Endo Children's Hosp
Birmingham, Alabama, United States
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California, United States
Yale School Of Medicine
New Haven, Connecticut, United States
Nemours Chld Clnc Jacksonville
Jacksonville, Florida, United States
Nemours Children's Health
Pensacola, Florida, United States
University of South Florida Diabetes Center
Tampa, Florida, United States
Children's Healthcare Atlanta
Atlanta, Georgia, United States
Columbus Research Foundation
Columbus, Georgia, United States
Indiana Uni School of Med-Ped
Indianapolis, Indiana, United States
University Of Louisville Research Foundation
Louisville, Kentucky, United States
Pennington Biomed Res Ctr
Baton Rouge, Louisiana, United States
Barry J. Reiner, MD LLC
Baltimore, Maryland, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
UBMD Peds-Div of Endo/Diabetes
Buffalo, New York, United States
UPMC Child Hosp-Pittsburgh
Pittsburgh, Pennsylvania, United States
Monument Health Clinical Rsrch
Rapid City, South Dakota, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Tech University HSC
Amarillo, Texas, United States
Univ Of Texas Hlth Science Cntr
San Antonio, Texas, United States
NE Clin Res of San Antonio
San Antonio, Texas, United States
Pediatric Endo UVHS
Charlottesville, Virginia, United States
Virginia Commonwealth University_Richmond
Richmond, Virginia, United States
Virginia Commonwealth Univ
Richmond, Virginia, United States
Gosford Hospital
Gosford, New South Wales, Australia
Westmead Children's Hospital- The Clinical Research Centre
Westmead, New South Wales, Australia
Women's & Children's Hospital
North Adelaide, South Australia, Australia
Monash Children's Hospital
Clayton, Victoria, Australia
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Perth Children's' Hospital
Nedlands, Western Australia, Australia
Universitätsklinik für Kinder und Jugendheilkunde Haus E
Salzburg, , Austria
UZ Brussel
Brussels, , Belgium
Cliniques Universitaires Saint-Luc - Serv. Pédiatrie
Brussels, , Belgium
CHU - UCL Namur - Site Sainte Elisabeth_Namur_1
Namur, , Belgium
Fakultní Nemocnice Ostrava
Ostrava-Poruba, , Czechia
Masarykova nemocnice v Usti nad Labem, o.z. - Detska klinika
Ústí nad Labem, , Czechia
University Hospital of Athens ATTIKON
Athens, Attica, Greece
University Hospital of Athens ATTIKON
Haidari-Athens, Attica, Greece
Henry Dunant Hospital Center,2nd Internal Medicine Clinic
Athens, , Greece
U.G.H. "Attikon", Pediatric Endocrinology Outpatient Clinic
Athens, , Greece
Athens Paediatric Center
Athens, , Greece
Iatriko Athinon (Athens Medical Canter)
Athens, , Greece
Henry Dunant Hospital Center,2nd Internal Medicine Clinic
Athens, , Greece
University General Hospital of Ioannina, Endocrinology
Ioannina, , Greece
General Hospital of Lamia
Lamia, , Greece
General Hospital of Lamia
Lamia, , Greece
Univ Gen Hospital Larisa
Larissa, , Greece
Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease
Larissa, , Greece
Pentelis Children's Hospital - Pediatric Clinic
Penteli, Athens, , Greece
"AHEPA" University General Hospital of Thessaloniki
Thessaloniki, , Greece
EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
Thessaloniki, , Greece
Endolife Specialty Hospitals
Guntur, Andhra Pradesh, India
Excel Endocrine Centre
Kolhāpur, Maharashtra, India
P D Hinduja National Hospital and Medical Research Centre
Mumbai, Maharashtra, India
All India Institute of Medical Sciences
New Dehli, New Delhi, India
Eternal Heart Care Centre
Jaipur, Rajasthan, India
Ramdev Rao Hospital
Hyderabad, Telangana, India
Dr P V Rao - Diabetes Research Centre
Hyderabad, Telangana, India
SSKM
Kolkata, West Bengal, India
Jothydev's Diabetes & Research Center
Thriruvananthapuram, , India
Soroka MC - Pediatric Endocrinology
Beersheba, , Israel
Rambam MC - Department of Pediatrics A
Haifa, , Israel
Chronic Care Center
Hazmiyeh, , Lebanon
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, Malaysia
University Malaya Medical Centre
Kuala Lumpur, , Malaysia
Hospital Putrajaya
Putrajaya, , Malaysia
Consultorio de Endocrinología y Pediatría
Puebla City, , Mexico
Hôpital d'Enfants
Rabat, , Morocco
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
De Kinderkliniek
Almere Stad, , Netherlands
Liggins Institute
Grafton, , New Zealand
PHI University Clinic for Children's Diseases-Skopje
Skopje, , North Macedonia
Hospital Da Luz S.A.
Lisbon, , Portugal
Unidade Local De Saude De Santa Maria E.P.E.
Lisbon, , Portugal
Centro Hospitalar de Vila Nova de Gaia
Vila Nova de Gaia, , Portugal
Ponce Med School Found Inc
Ponce, , Puerto Rico
Spitalul Judetean de Urgenta Targoviste
Târgovişte, Dâmbovița County, Romania
Diabet Center SRL
Brasov, , Romania
Spitalul Clinic de Urgenta pentru Copii "M.S.Curie"
Bucharest, , Romania
Emergency County Hospital Constanta
Constanța, , Romania
Republic Children's Hospital of Ministry of Health of Udmurt
Izhevsk, , Russia
RMAPE
Moscow, , Russia
NSMU paediatric clinic
Novosibirsk, , Russia
GFHI Omsk Region "Regional Children's Clinical Hospital"
Omsk, , Russia
SPSBHI City Children out-patient clinic #44
Saint Petersburg, , Russia
Siberian State Medical University
Tomsk, , Russia
SAHI Sverdlovsk Reg "Regional Children's Clinical Hospital"
Yekaterinburg, , Russia
Taipei Mackay Memorial Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital Linkou-Dept of Pediatrics
Taoyuan District, , Taiwan
City Clinical Hospital #9 (Dnipro) - Endocrinology department
Dnipro, , Ukraine
CNPE "City Clinical Hospital #9 Dnipro City Council"
Dnipro, , Ukraine
Kharkiv Regional Children's Clinical Hospital - Endocrinological department
Kharkiv, , Ukraine
Ukrainian scientific and practical center of endocrine surgery of MOH - department of paediatric endocrinology
Kiev, , Ukraine
"Verum clinic" LLC
Kyiv, , Ukraine
Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
Kyiv, , Ukraine
Vinnytsia Regional Clinical Endocrinological Centre - Therapeutic department #2
Vinnytsia, , Ukraine
Birmingham Children's Hospital
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1218-1527
Identifier Type: OTHER
Identifier Source: secondary_id
2018-002952-34
Identifier Type: REGISTRY
Identifier Source: secondary_id
NN9924-4437
Identifier Type: -
Identifier Source: org_study_id